NeoGenomics to Acquire Genoptix

NeoGenomics, Inc. (NEO) announced on October 23 that the company has entered into a definitive agreement to acquire Genoptix, Inc. NeoGenomics will pay $125 million in cash plus 1 million shares of NeoGenomics common stock according to the agreement. Genoptix is a leading clinical oncology laboratory, and NeoGenomics is the leading provider of cancer-focused genetic testing services.

 

Sonal notified subscribers of the news event at 7:00 am. The next trade took place at $13.50 when the market opened for regular trading. NeoGenomics closed at $14.10 on the event day. The stock price continued to rise over the next five trading sessions before closing at $17.73 on October 31. That marks a gain of 31.33% in the week following the announcement.

Find out more about how you can trade on stock acquisition announcements in the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!